Research & Literature

Primary Biliary Cholangitis--A New Name and a New Treatment.

Pratt DS

The New England journal of medicine 2016; (375(7)):685-7 doi:10.1056/NEJMe1607744.

Positive antimitochondrial antibody but normal serum alkaline phosphatase levels: Could it be primary biliary cholangitis?

Berdichevski T, Cohen-Ezra O, Pappo O, Ben-Ari Z

Hepatology research : the official journal of the Japan Society of Hepatology 2017; (47(8)):742-746 doi:10.1111/hepr.12809.

Nailfold digital capillaroscopic findings in patients with diffuse and limited cutaneous systemic sclerosis.

Shenavandeh S, Haghighi MY, Nazarinia MA

Reumatologia 2017; (55(1)):15-23 doi:10.5114/reum.2017.66683.

Recent advances in the management of pruritus in chronic liver diseases.

Tajiri K, Shimizu Y

World journal of gastroenterology 2017; (23(19)):3418-3426 doi:10.3748/wjg.v23.i19.3418.

Detection of anti-mitochondrial antibodies by immunoprecipitation in patients with systemic sclerosis.

Ceribelli A, Isailovic N, De Santis M, et al.

Journal of immunological methods 2018; (452()):1-5 doi:10.1016/j.jim.2017.10.001.

Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.

Lindor KD, Bowlus CL, Boyer J, et al.

Hepatology (Baltimore, Md.) 2019; (69(1)):394-419 doi:10.1002/hep.30145.

Cholestatic liver diseases: new targets, new therapies.

Santiago P, Scheinberg AR, Levy C

Therapeutic advances in gastroenterology 2018; (11()):1756284818787400 doi:10.1177/1756284818787400.

Current Status of Liver Transplantation for Primary Biliary Cholangitis.

Aguilar MT, Carey EJ

Clinics in liver disease 2018; (22(3)):613-624 doi:10.1016/j.cld.2018.03.011.

Mechanisms and Treatments of Pruritus in Primary Biliary Cholangitis.

Shah RA, Kowdley KV

Seminars in liver disease 2019; (39(2)):209-220 doi:10.1055/s-0039-1679918.

Aminaphtone Efficacy in Primary and Secondary Raynaud's Phenomenon: A Feasibility Study.

Ruaro B, Pizzorni C, Paolino S, et al.

Frontiers in pharmacology 2019; (10()):293 doi:10.3389/fphar.2019.00293.

Drug Therapies for Chronic Cholestatic Liver Diseases.

Wagner M, Fickert P

Annual review of pharmacology and toxicology 2020; (60()):503-527 doi:10.1146/annurev-pharmtox-010818-021059.

From pruritus to CREST syndrome in a middle aged woman.

Karakousis ND, Kanakas CA

Journal of frailty, sarcopenia and falls 2017; (2(1)):6-8.

Association Between Centromere- and Topoisomerase-specific Immune Responses and the Degree of Microangiopathy in Systemic Sclerosis.

van Leeuwen NM, Wortel CM, Fehres CM, et al.

The Journal of rheumatology 2021; (48(3)):402-409 doi:10.3899/jrheum.191331.

Multiple Autoimmune Syndrome: An Unusual Combination of Autoimmune Disorders.

Sarfaraz S, Anis S

Reviews on recent clinical trials 2020; (15(3)):240-243 doi:10.2174/1574887115666200621184110.

Review article: pathophysiology and management of primary biliary cholangitis.

Leung KK, Deeb M, Hirschfield GM

Alimentary pharmacology & therapeutics 2020; (52(7)):1150-1164 doi:10.1111/apt.16023.

Anti-centromere antibodies target centromere-kinetochore macrocomplex: a comprehensive autoantigen profiling.

Kajio N, Takeshita M, Suzuki K, et al.

Annals of the rheumatic diseases 2021; (80(5)):651-659 doi:10.1136/annrheumdis-2020-218881.

Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis.

Floreani A

Journal of experimental pharmacology 2020; (12()):643-652 doi:10.2147/JEP.S267375.

Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis.

Soret PA, Lam L, Carrat F, et al.

Alimentary pharmacology & therapeutics 2021; (53(10)):1138-1146 doi:10.1111/apt.16336.

Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis.

Ahmed F, Maclean RH, Nihtyanova SI, et al.

Rheumatology (Oxford, England) 2022; (61(2)):781-786 doi:10.1093/rheumatology/keab395.

Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study.

Reig A, Álvarez-Navascués C, Vergara M, et al.

The American journal of gastroenterology 2021; (116(11)):2250-2257 doi:10.14309/ajg.0000000000001343.

Advances in nailfold capillaroscopic analysis in systemic sclerosis.

Ruaro B, Sulli A, Smith V, et al.

Journal of scleroderma and related disorders 2018; (3(2)):122-131 doi:10.1177/2397198318757699.

Systemic sclerosis and primary biliary cholangitis: An overlapping entity?

Lepri G, Bellando Randone S, Matucci Cerinic M, Allanore Y

Journal of scleroderma and related disorders 2019; (4(2)):111-117 doi:10.1177/2397198318802763.

Bilateral calcinosis cutis of orbital walls in CREST syndrome.

Ghadimi H, Nikdel M, Eshraghi B

Journal of scleroderma and related disorders 2019; (4(2)):NP1-NP4 doi:10.1177/2397198318819383.

Management of Raynaud's phenomenon in systemic sclerosis-a practical approach.

Fernández-Codina A, Cañas-Ruano E, Pope JE

Journal of scleroderma and related disorders 2019; (4(2)):102-110 doi:10.1177/2397198318823951.

Nailfold capillaroscopy in systemic sclerosis - state of the art: The evolving knowledge about capillaroscopic abnormalities in systemic sclerosis.

Lambova SN, Müller-Ladner U

Journal of scleroderma and related disorders 2019; (4(3)):200-211 doi:10.1177/2397198319833486.

A case of autoimmune hepatitis-Primary biliary cholangitis overlap syndrome without any associated autoantibody.

Lee KI, Wei YC, Yeh ML

The Kaohsiung journal of medical sciences 2022; (38(7)):712-713 doi:10.1002/kjm2.12545.

Aberrant cytokeratin 7 expression by hepatocytes can predict the ductopenia grade in primary biliary cholangitis.

Liu HL, Yang AY, Xiong QF, et al.

BMC gastroenterology 2022; (22(1)):443 doi:10.1186/s12876-022-02538-w.

Efficacy of Fractional CO2 Laser for Improvement of Limited Mouth Opening in Systemic Sclerosis.

Bhat YJ, Bashir Y, Latif I, et al.

Journal of cutaneous and aesthetic surgery 2022; (15(4)):387-393 doi:10.4103/JCAS.JCAS_29_21.

Overlap syndrome of primary biliary cholangitis and primary sclerosing cholangitis: two case reports.

Yacoub H, Ben Azouz S, Hassine H, et al.

Journal of medical case reports 2023; (17(1)):169 doi:10.1186/s13256-023-03908-y.

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.

Hirschfield GM, Shiffman ML, Gulamhusein A, et al.

Hepatology (Baltimore, Md.) 2023; (78(2)):397-415 doi:10.1097/HEP.0000000000000395.

Systemic sclerosis and primary biliary cholangitis: Longitudinal data to determine the outcomes.

Lepri G, Airò P, Distler O, et al.

Journal of scleroderma and related disorders 2023; (8(3)):210-220 doi:10.1177/23971983231155948.

Treatment of Primary Biliary Cholangitis including Transplantation.

Muzahim Y, Wakil A, Bassi M, Pyrsopoulos N

Clinics in liver disease 2024; (28(1)):103-114 doi:10.1016/j.cld.2023.07.003.

Diagnostic value of anti-mitochondrial antibody in patients with primary biliary cholangitis: A systemic review and meta-analysis.

Xu Q, Zhu W, Yin Y

Medicine 2023; (102(45)):e36039 doi:10.1097/MD.0000000000036039.

Long-term outcomes in patients with primary biliary cholangitis complicated with CREST syndrome.

Abe K, Hayashi M, Sugaya T, et al.

Scientific reports 2024; (14(1)):14124 doi:10.1038/s41598-024-64976-8.

Epigastric discomfort in a young woman: unveiling a case of CREST syndrome.

Gupta P, Adhikari P, Sitaula D, et al.

Annals of medicine and surgery (2012) 2024; (86(11)):6721-6725 doi:10.1097/MS9.0000000000002420.

Liver Failure in Autoimmune Hepatitis Overlap Syndrome With Primary Biliary Cholangitis: A Case Report.

Batista M, Brito P, Miranda P, et al.

Cureus 2024; (16(11)):e73574 doi:10.7759/cureus.73574.

Use of nailfold capillaroscopy for the early diagnosis of systemic sclerosis in patients with primary biliary cholangitis.

Crescenzi D, Balducci D, Mazzetti M, et al.

Annals of gastroenterology 2025; (38(2)):187-194 doi:10.20524/aog.2025.0949.

Systemic Sclerosis and Primary Biliary Cholangitis: A Comprehensive Review of Two Overlapping Rare Entities With Insights on Diagnostics and Management.

Thakkar HH, Mathew NV, Reddy EP, et al.

Cureus 2025; (17(4)):e82008 doi:10.7759/cureus.82008.

Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results.

Levy C, Trivedi PJ, Kowdley KV, et al.

The American journal of gastroenterology 2025; doi:10.14309/ajg.0000000000003603.

Anti-centromere antibody positivity with coexisting idiopathic portal hypertension and primary biliary cholangitis progressing to limited cutaneous systemic sclerosis: a case report.

Ando Y, Mabuchi S, Mataki N, et al.

Journal of medical case reports 2025; (19(1)):392 doi:10.1186/s13256-025-05426-5.

Fractional Carbon Dioxide Laser for the Treatment of Microstomia in Limited-Cutaneous Systemic Sclerosis.

Fisher C, Woodside SS, Martin YE, et al.

Lasers in surgery and medicine 2025; (57(8)):658-662 doi:10.1002/lsm.70057.

A comprehensive review of systemic sclerosis-primary biliary cholangitis overlap: emerging evidence for a distinct clinical subtype.

Memon A, Nadella M, Emokpae M, Assis DN

Current opinion in rheumatology 2025; (37(6)):413-421 doi:10.1097/BOR.0000000000001127.

Advancing the management of primary biliary cholangitis: From pathogenesis to emerging therapies.

Curto A, Iamello RG, Lynch EN, Galli A

World journal of clinical cases 2025; (13(30)):109028 doi:10.12998/wjcc.v13.i30.109028.

Clinical outcomes and early- prognostic biomarkers of primary biliary cholangitis with ductopenia.

Wang W, Zhang G, Liu H, et al.

Frontiers in immunology 2025; (16()):1680942 doi:10.3389/fimmu.2025.1680942.

Systemic sclerosis and primary biliary cholangitis: a systematic review of case-control studies comparing isolated and overlapping disease phenotypes.

Nursoy M, Mehmetoglu E, Syal A, et al.

Journal of scleroderma and related disorders 2026; (11(1)):e000002 doi:10.1136/jsrd-2026-000002.